Evidence map›Paper›PMID 28778876›Full record

ArticleMolecular cancer research : MCR2017

Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Vy M Tran, Anna Wade, Andrew McKinney, Katharine Chen, Olle R Lindberg, Jane R Engler, Anders I Persson, Joanna J Phillips

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Heparan Sulfate Synthesized byMolecular cancer research : MCR · 2021
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vy M TranDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Anna WadeDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Andrew McKinneyDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Katharine ChenDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Olle R LindbergDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Jane R EnglerDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Anders I PerssonDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Joanna J PhillipsDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California. Joanna.phillips@ucsf.edu.
Neurological Surgery · USUniversity of California, San Francisco · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
YEAST THREONINE &SERINE KINASESP41RR001614 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ORTIZ DE MONTELLANO, PAUL R · 1985 to 2011
$24.1M
Therapeutic assessment of synthetic heparin sulfates in transplantation modelsP01HL107152 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2011 to 2017
$15.8M
Extracellular Sulfatases As Novel Biomarkers For Early Detection of CancerU01CA168878 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEMJABBAR-ALAOUI, HASSAN, PHILLIPS, JOANNA · 2012 to 2016
$2.2M
Heparan sulfate proteoglycans as critical regulators of brain cancer malignancyR01NS081117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2012 to 2016
$1.7M
NCI NIH HHS P50 CA097257NCI NIH HHS U01 CA168878NCRR NIH HHS P41 RR001614NHLBI NIH HHS P01 HL107152NINDS NIH HHS R01 NS081117
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor of adults and confers a poor prognosis due, in part, to diffuse invasion of tumor cells. Heparan sulfate (HS) glycosaminoglycans, present on the cell surface and in the extracellular matrix, regulate cell signaling pathways and cell-microenvironment interactions. In GBM, the expression of HS glycosaminoglycans and the enzymes that regulate their function are altered, but the actual HS content and structure are unknown. However, inhibition of HS glycosaminoglycan function is emerging as a promising therapeutic strategy for some cancers. In this study, we use liquid chromatography-mass spectrometry analysis to demonstrate differences in HS disaccharide content and structure across four patient-derived tumorsphere lines (GBM1, 5, 6, 43) and between two murine tumorsphere lines derived from murine GBM with enrichment of mesenchymal and proneural gene expression (mMES and mPN, respectively) markers. In GBM, the heterogeneous HS content and structure across patient-derived tumorsphere lines suggested diverse functions in the GBM tumor microenvironment. In GBM5 and mPN, elevated expression of sulfatase 2 (SULF2), an extracellular enzyme that alters ligand binding to HS, was associated with low trisulfated HS disaccharides, a substrate of SULF2. In contrast, other primary tumorsphere lines had elevated expression of the HS-modifying enzyme heparanase (HPSE). Using gene editing strategies to inhibit HPSE, a role for HPSE in promoting tumor cell adhesion and invasion was identified. These studies characterize the heterogeneity in HS glycosaminoglycan content and structure across GBM and reveal their role in tumor cell invasion.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorChromatography, LiquidGene EditingGlioblastomaGlucuronidaseHeparanaseHeparan SulfateHumansMass SpectrometryMiceNeoplasm InvasivenessNeoplasm TransplantationSignal TransductionSulfatasesGlucuronidaseHeparanaseHeparan SulfateSULF2 protein, humanSulfatasesSulfotransferases

Identifiers

PMID28778876
PMCPMC6059807
OpenAlexW2743066775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.